^
    Back
    Association details:
    Biomarker:PGR expression
    Cancer:Breast Cancer
    Drug:Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

    Excerpt:
    ...- Patients with known estrogen and/or progesterone receptor-expressing tumors may have additionally been treated with hormonal therapy....
    Trial ID:
    NCT00337103
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

    Excerpt:
    ...Patients with known estrogen and/or progesterone receptor-expressing tumors may have additionally been treated with hormonal therapy 7....
    Trial ID:
    NCT03412955
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    326P - National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study

    Published date:
    09/13/2021
    Excerpt:
    Metastatic breast cancer pts treated by ERI in 2nd, 3rd or 4th line between Sep-2011 and June-2018 were selected.…Predictive factors of PFS in univariate analysis were progesterone receptor expression (p=0.014), number of ERI infusions (p=0.011) and duration of response (p<0.001)...
    Trial ID:
    Loreline